May 11, 1997 |
Generic drugs, those low-priced copies of brand-name medicines, are so popular that they now make up nearly half the 2.4 billion prescriptions written in this country every year. That popularity hasn't filtered down to the bottom lines of the generic drug makers, however, and the industry's troubles mean consumers could soon see prices rising and their selection limited. Last year, heavy competition slashed the industry's profits and stock prices.
May 21, 1993 |
Maxicare Health Plans' doctors are urged to prescribe generic drugs when possible. The result: About 40% of all prescriptions are now filled by generics--a $5-million savings last year in the HMO's drug purchasing budget. San Diego allergist Dr. Eli Meltzer used to prescribe a brand-name drug called Theodor only for his asthma patients. But recently, he has been comfortable recommending a generic version of the medication for unclogging bronchial tubes. His patients save $12 a prescription.
December 11, 2008 |
Finally, a little good healthcare news for consumers: U.S. prices for generic prescription drugs, which already cost as little as one-third what their brand-name cousins do, have been getting cheaper and probably will keep doing so. The causes? The ultra-low prices for generic prescriptions offered by giant retailers and drugstore chains and intense competition among the many generic drug makers fighting for sales, according to health information firm IMS Health Inc.
January 3, 2006 |
Makers of generic drugs are gearing up for a big year as blockbuster brand-name medicines such as Zocor, Zoloft, Pravachol and Ambien are set to lose U.S. patent protection. But analysts caution that stocks in producers of cheaper versions of those drugs are not sure bets. Many stocks in generic-drug makers already had a strong 2005 ahead of the opportunity -- notably Teva Pharmaceutical Industries Ltd., Ivax Corp. and Barr Pharmaceuticals Inc.
March 31, 1995 |
In a deal that would create one of the nation's largest makers of generic drugs, Corona-based Watson Pharmaceuticals on Thursday agreed to buy Circa Pharmaceuticals in a stock-swap deal valued at nearly $600 million. The acquisition would become the latest in a string of drug industry mergers as former rivals join forces in the face of government and corporate efforts to cut costs.
March 14, 2006 |
Making a bid to stay near the top in the eat-or-be-eaten generic-drug business, Corona-based Watson Pharmaceuticals Inc. said Monday that it would buy a smaller rival for $1.9 billion in cash. Under the deal, Watson would pay $25 a share for Davie, Fla.-based Andrx Corp. The purchase, which must be approved by Andrx shareholders and federal regulators, is expected to be final in six months.
March 17, 2008 |
In the contentious debate over insuring Americans' health, the value of generic prescription drugs is a rare point of consensus. Patients, physicians, employers, politicians -- all hail generics as powerful treatment for a swelling healthcare tab. On average, these copycat medicines cost less than a third of the brand-name drugs they mimic. In turn, the competition they provide drives down the cost of those first-to-market drugs.
October 18, 2001 |
To stave off panic and hoarding of the name-brand antibiotic Cipro, the U.S. Food and Drug Administration this week is expected to approve two common antibiotics for treatment of the virulent inhaled form of anthrax. The move comes as supplies of Cipro are dwindling so quickly that pharmacies and wholesalers have begun to ration it. "We hope that this will make the lay public understand that there are alternative antibiotics available," said Dr.
September 15, 2003 |
Seeking to rein in soaring prescription drug costs, four of California's biggest health plans will use financial incentives in a campaign to convert members from expensive brand-name medicines to generic equivalents.